Jove
Visualize
联系我们
JoVE
x logofacebook logolinkedin logoyoutube logo
关于 JoVE
概览领导团队博客JoVE 帮助中心
作者
出版流程编辑委员会范围与政策同行评审常见问题投稿
图书馆员
用户评价订阅访问资源图书馆顾问委员会常见问题
研究
JoVE JournalMethods CollectionsJoVE Encyclopedia of Experiments存档
教育
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教师资源中心教师网站
使用条款与条件
隐私政策
政策

相关概念视频

Blood Studies for Cardiovascular System I: Cardiac Biomarkers01:20

Blood Studies for Cardiovascular System I: Cardiac Biomarkers

746
Cardiac biomarkers are enzymes, proteins, and hormones released into the blood when cardiac cells are injured. They are powerful tools for triaging.
The essential diagnostic tools for detecting myocardial necrosis and monitoring individuals suspected of having acute coronary syndrome (ACS) include:
Troponins
Troponins, particularly cardiac troponins I and T, are the most precise and sensitive markers of myocardial injury. They are detectable within 4-6 hours of myocardial injury and remain...
746
Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers01:19

Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers

511
Cardiac biomarkers are critical in diagnosing, prognosing, and managing cardiovascular diseases. Routine measurement of specific biomarkers such as B-type natriuretic peptide (BNP), C-reactive protein (CRP), and homocysteine (Hcy) is common practice in clinical settings to evaluate heart function and predict cardiovascular events.
These markers indicate stress or strain on the heart muscle:
Natriuretic Peptides (BNP)
Cardiac myocytes produce these hormones in response to ventricular stretching...
511

您也可能阅读

相关文章

通过共同作者、期刊和引用图与本文相关的文章。

排序
Same author

'An adrenaline-fueled emergency': a qualitative thematic analysis of reviews of deaths in England where DNACPR (Do Not Attempt Cardiopulmonary Resuscitation) recommendations are not implemented for people with a learning disability.

BMJ open·2026
Same author

Caregiver-Associated Physical Activity Patterns, Dietary Behaviors and Interventional Beliefs in Individuals with Down Syndrome: Insights from a Large European Survey.

Nutrients·2026
Same author

Understanding Obesity in Individuals with Down Syndrome: Caregiver Perceptions, Awareness, and Motivation.

Nutrients·2026
Same author

Promoting Research Excellence in Down Syndrome: Proceedings of the 5th International Conference of the Trisomy 21 Research Society.

Neuromolecular medicine·2026
Same author

Prevalence of multiple morbidities and cancers in individuals with Down syndrome: A matched descriptive study using linked electronic health record data.

PloS one·2026
Same author

Psychometric properties of the Norwegian CAMDEX-DS-II and CAMCOG-DS-II for dementia assessment in adults with Down syndrome: A national multi-site clinical study.

Research in developmental disabilities·2026
Same journal

Multimorbidity burden and patterns associated with DeepBrainNet-derived brain-age gap in dementia-free older adults: A community-based study.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2026
Same journal

Reply to "Shifting the emphasis of brain health literacy from individuals to systems to reduce inequalities".

Alzheimer's & dementia : the journal of the Alzheimer's Association·2026
Same journal

Shifting the emphasis of brain health literacy from individuals to systems to reduce inequalities.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2026
Same journal

Correlates and predictors of self-efficacy among dementia caregivers: D-CARE findings.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2026
Same journal

What should convince a clinician of disease modification in Alzheimer's disease clinical trials?

Alzheimer's & dementia : the journal of the Alzheimer's Association·2026
Same journal

Primary cilia-extracellular vesicle crosstalk in Alzheimer's disease: Emerging mechanisms and biomarker potential.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2026
查看所有相关文章

相关实验视频

Updated: Jan 7, 2026

Dried Blood Spot Collection of Health Biomarkers to Maximize Participation in Population Studies
07:20

Dried Blood Spot Collection of Health Biomarkers to Maximize Participation in Population Studies

Published on: January 28, 2014

37.1K

生物标志物 生物标志物

Mina Idris1, Fedal Saini1, Phoebe Ivain1

  • 1King's College London, London, United Kingdom.

Alzheimer's & dementia : the journal of the Alzheimer's Association
|December 25, 2025
PubMed
概括
此摘要是机器生成的。

患有唐氏综合征 (DS) 的个人表现出早期阿尔茨海默病 (AD) 生物标志物变化,类似于其他AD形式. 基于事件的模型 (EBM) 有助于对这些变化进行测序,可能使得DS的早期诊断成为可能.

更多相关视频

Selecting Multiple Biomarker Subsets with Similarly Effective Binary Classification Performances
07:35

Selecting Multiple Biomarker Subsets with Similarly Effective Binary Classification Performances

Published on: October 11, 2018

7.9K
Ecotoxicological Methodologies to Evaluate Biomarkers at Different Scales in Neotropical Anurans
08:14

Ecotoxicological Methodologies to Evaluate Biomarkers at Different Scales in Neotropical Anurans

Published on: April 28, 2023

699

相关实验视频

Last Updated: Jan 7, 2026

Dried Blood Spot Collection of Health Biomarkers to Maximize Participation in Population Studies
07:20

Dried Blood Spot Collection of Health Biomarkers to Maximize Participation in Population Studies

Published on: January 28, 2014

37.1K
Selecting Multiple Biomarker Subsets with Similarly Effective Binary Classification Performances
07:35

Selecting Multiple Biomarker Subsets with Similarly Effective Binary Classification Performances

Published on: October 11, 2018

7.9K
Ecotoxicological Methodologies to Evaluate Biomarkers at Different Scales in Neotropical Anurans
08:14

Ecotoxicological Methodologies to Evaluate Biomarkers at Different Scales in Neotropical Anurans

Published on: April 28, 2023

699

科学领域:

  • 神经学 神经学
  • 生物标志物 生物标志物
  • 遗传学 是一个遗传学.

背景情况:

  • 患有唐氏综合征 (DS) 的人患阿尔茨海默氏病 (AD) 的风险明显更高,病理通常在三十多岁时出现.
  • 在DS中临床AD之前的血生物标志物,认知和神经成像变化的精确序列尚不清楚.
  • 基于事件的模型 (EBM) 是一种数据驱动的方法,用于从横截面数据中估计疾病进展序列,并考虑个人变异性.

研究的目的:

  • 将EBM应用于患有DS的成年人队列,以确定AD诊断前生物标志物,认知和神经成像变化的序列.
  • 为了沿着这种已识别的疾病进展序列将DS患者分阶段.

主要方法:

  • 利用基于事件的模型 (EBM) 对60名患有唐氏综合征 (DS) 并且目前没有AD诊断的成年人的数据.
  • 检查了临床评估,血生物标志物 (例如,粉样蛋白-β 42/40比率,p-tau,NfL,GFAP),并将纳入结构性MRI数据.
  • 旨在建立临床前AD变化的多模式序列.

主要成果:

  • 初步发现表明,早期的AD变化在DS中反映了零星和家族AD中的变化.
  • 观察到的序列:血氨基酸-β 42/40 的比例变化,其次是记忆力下降,神经退行症标志物 (p-tau, NfL),执行功能障碍,视觉运动缺陷,以及后来的神经炎症 (GFAP).
  • 结构性MRI数据将被整合在一起,以完善多模态进展序列.

结论:

  • 这项研究完善了对DS中AD进展时间的理解,有助于优化认知测试,神经成像和血液采样策略.
  • EBM提供了个体级别的分期,这可以促进早期诊断,并改善AD患者群体中AD的临床试验设计.
  • 整合多种数据模式 (血生物标志物,认知,神经成像) 可以更深入地了解DS患者临床前AD阶段的情况.